ArticleBurns & trauma2014
Chronic allograft rejection: A significant hurdle to transplant success.
Article in Burns & trauma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of C4d and donor specific antibodies in face and hand transplantation-a systematic review.Frontiers in transplantation · 2024Pooled it
- A modified mouse heart transplant model with extended aorta enables analysis of vascular continuity in cardiac allograft vasculopathy.JHLT open · 2026Article
- Mortality and graft loss in face transplantation: lessons from two decades of experience.Clinical transplantation and research · 2026Review
- Blood vessels as primary site of rejection in murine lung transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Podosomes and Mechanical Force.Results and problems in cell differentiation · 2026Review
- Vascular Remodeling in Chronic Rejection: Insights into Transplant Vasculopathy Across Solid Organ Allografts.Results and problems in cell differentiation · 2026Review
- Macrophage Actin Cytoskeleton in Chronic Rejection.Results and problems in cell differentiation · 2026Review
- Article
- Chronic rejection models for vascularized composite tissue allotransplantation.Scientific reports · 2025Article
- Repurposing Histone Deacetylase Inhibitors for Management of Solid Organ Transplant Rejection.Results and problems in cell differentiation · 2025Review
- An innovative ear transplantation for vascularized composite allotransplantation research in porcine model.Scientific reports · 2024Article
- Accelerating Oral Wound Healing Using Bilayer Biomaterial Delivery of FTY720 Immunotherapy.Advanced healthcare materials · 2024Article
- Article
- Extra-articular blocking technique for acetabular bone defect reconstruction.Annals of joint · 2024Article
- Role of Complement-dependent Cytotoxicity Crossmatch and HLA Typing in Solid Organ Transplant.Reviews on recent clinical trials · 2024Review
- Exploring the molecular mechanisms of macrophages in islet transplantation using single-cell analysis.Frontiers in immunology · 2024Article
- Advances in Fabrication Technologies for the Development of Next-Generation Cardiovascular Stents.Journal of functional biomaterials · 2023Review
- M1/M2 macrophages and their overlaps - myth or reality?Clinical science (London, England : 1979) · 2023Article
- PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.Cells · 2023Review
- Extra-articular Blocking Technique to Resolve Severe Acetabular Bone Defect in Developmental Dysplasia of the Hip.Orthopaedic surgery · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The state-of-the-art immunosuppression drugs do not ensure indefinite transplant survival, and most transplants are continuously lost to chronic rejection even years posttransplantation. This form of rejection is responsible for long-term failure of transplanted organs. The mechanisms involved in development of chronic rejection are not well-understood. One of the main features of chronic rejection is progressive luminal narrowing of graft vessels, which results in compromised blood flow, ischemia, cell death, and finally graft failure. All the existing immunosuppressive regimens are targeting acute rejection, and at present there is no available therapy for prevention of chronic rejection. Chronic rejection involves two major, but interrelated responses: The first is the host immune response against the transplant mediated primarily by alloreactive T and B cells, and the second is injury and repair of the graft (vasculopathy of graft vessels). Here we focus on recent advances in understanding the cellular and molecular aspects of chronic transplant vasculopathy and function of macrophages, topics pivotal for development of novel antichronic rejection therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.